Equity Field Notes from temporal sources

[DanWebzster]

HPPI is an OTCQB Pharma with several milestones during the rest of 2018, including:

1) Ph2b pivotal resutls
2) NDA submission
3) Commercialization Strategy

holds the exclusive USA license for potent best-in-class Hedgehog Inhibitor.

FDA approval could come H-1/2019

Lead program is targeted at Basal Cell Carcinoma Nevus.

With Ph2b results, the lead program may be eligible for fast track status.

This program is partnered with Mayne Pharma, an Australian ASX-listed company which is also the majority shareholder of HPPI. This relationship is so dominant that it may/probably does disadvantage HPPI shareholders.

Still, uplisting and significant upside is a possible for HPPI shares.